Concert Pharmaceuticals (CNCE) Financials

$8.37

$0.00 (0.00%)

As on 06-Mar-2023 09:30EDT

Market cap

$402 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1.7

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	0.06	0.03	7.90	1.08	10.51	143.89
Cost of Revenue	--	--	--	59.82	43.15	30.22
Gross Profit	0.04	32.58	0.01	1.08	10.51	143.89
Operating Expenses	67.47	0.11	80.55	80.09	66.09	51.24
Operating Profit (EBIT)	-124.27	-77.51	-72.65	-79.02	-55.58	92.65
Other Income	-0.93	-0.46	-2.20	0.85	-0.13	2.69
Profit before Tax	-67.59	-0.08	-74.85	-78.17	-55.71	95.34
Provision for Tax	--	--	-0.09	--	0.31	-0.30
Profit after Tax (Net Income)	-67.59	-0.08	-74.77	-78.17	-56.02	95.64
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-126.81	-80.05	-74.77	-78.17	-56.02	95.20

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	133.27	112.23	131.16	101.46	167.74	196.43
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	20.46	36.97	17.92	18.75	16.06	8.86
Current Liabilities	17.40	16.12	10.18	17.27	8.75	6.45
Total Liabilities	188.53	165.32	159.26	137.47	192.55	211.74

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	13.94	14.99	16.54	20.62	12.40	6.00
Current Assets	157.20	150.33	142.72	116.86	180.15	205.73
Total Assets	188.53	165.32	159.26	137.47	192.55	211.74
Total Debt*	14.21	1.16	16.00	16.26	--	--
Net Current Assets	139.80	134.21	132.55	99.59	171.40	199.29

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-55.15	-69.04	-48.76	-48.03	102.93
Cash Flow from Investing Activities	--	52.46	0.34	82.58	37.90	-121.31
Cash from Financing Activities	--	67.13	92.85	1.45	-0.17	5.49
Net Cash Inflow / Outflow	--	64.43	24.16	35.27	-10.30	-12.89

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	-1.51	0.00	-2.41	-3.26	-2.44	4.16
Cash EPS ($)	--	0.04	-2.36	-3.19	-2.38	4.20
Adjusted Book Value ($)	--	3.30	4.23	4.23	7.29	8.54
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-1.62	-2.23	-2.03	-2.09	4.48
Free Cash Flow per Share ($)	--	-1.63	-2.23	-2.06	-2.21	4.43

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-0.06	-56.45	-54.76	-30.77	67.82
ROE (%)	-64.42	-0.07	-64.28	-58.07	-30.77	67.82
ROA (%)	-41.12	-0.05	-50.39	-47.37	-27.72	61.28
EBIT Margin (%)	-119,465.25	-245.72	-947.24	-7,257.75	-530.33	66.82
Net Margin (%)	7,720.97	18.73	-1,312.14	-4,058.46	-539.83	65.25
Cash Profit Margin (%)	-0.09	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	-99.83	-1.00	6.34	-0.90	-0.93	825.96
EBIT Growth (%)	-1.93	99.89	4.24	-40.31	-157.94	289.58
Net Profit Growth (%)	-1.93	99.89	4.35	-39.52	-158.58	288.56
EPS Growth (%)	25.14	1.00	0.26	-0.34	-1.59	2.80
Book Value Growth (%)	-8.61	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	-1,337.90	-5.24	-2.83	-5.15	6.22
Price / Book Value	1.67	0.95	2.99	2.18	1.72	3.03
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.70	-24.91	-3.77	-1.65	-2.35	4.03
Close Price ($)	6.70	3.15	12.64	9.23	12.55	25.87
High Price ($)	7.37	13.44	13.50	17.83	28.40	30.71
Low Price ($)	2.57	2.64	5.47	5.36	10.80	8.61
Market Cap ($ Cr)	401.95	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	--	0.01	0.12	0.16	--	--
Short term debt to equity ratio	0.01	0.02	0.01	0.00	--	--
Current Ratio	9.03	9.33	14.02	6.77	20.59	31.92
Quick Ratio	9.03	--	--	--	--	31.92
Interest Coverage	--	--	--	--	--	117.98

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	2,912.79	669.16	40.21	30.83	157.74	0.54
Asset Turnover	0.00	0.00	0.05	0.01	0.05	0.92
Receivable days	--	19,031.61	81.10	2,866.21	301.69	1.24
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	6.59	8.19	7.27
Cash Conversion Cycle	--	--	--	--	293.50	-6.03

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.